Bolt - BOLT

Bolt Biotherapeutics Azioni (NASDAQ: BOLT)

Ultime notizie per Bolt Biotherapeutics (NASDAQ:BOLT) Azioni

Bolt Biotherapeutics

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics Inc

BOLT

Bolt Metals Corp

Bolt Projects Holdings, Inc. - Common Stock

Bolt Projects Holdings Inc

HC Wainwright &amp; Co. analyst Edward White reiterates Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) with a Neutral.

News

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Neutral on Bolt Biotherapeutics

Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.35) by 14.29 percent. The company reported quarterly sales of $1.141 million which missed the analyst consensus estimate of $1.263 million by 9.64 percent. This is a 54.87 percent decrease over sales of $2.528 million the same period last year.

Earnings

Earnings Misses

Bolt Biotherapeutics Q3 2024 GAAP EPS $(0.40) Misses $(0.35) Estimate, Sales $1.141M Miss $1.263M Estimate

BDC-4182 demonstrated compelling anti-tumor activity and an acceptable safety profile in preclinical studies
BDC-4182 outperformed cytotoxic claudin 18.2 ADCs in syngeneic model
Learnings from BDC-1001 data suggest Boltbody&#x2122;&nbsp;ISACs with enhanced immune activation could offer greater efficacy, warranting further testing
REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today presented updated preclinical data for BDC-4182, a next-generation Boltbody&#x2122;&nbsp;ISAC clinical candidate targeting claudin 18.2, and provided key learnings from its Phase 1 dose-escalation trial of BDC-1001 at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held in Houston, Texas from November 6-10, 2024.

Biotech

General

Bolt Biotherapeutics Presents Updated Preclinical Data For BDC-4182 And Key Learnings From Phase 1 Dose-Escalation Trial Of BDC-1001 At SITC Annual Meeting; BDC-4182 Demonstrated Compelling Anti-tumor Activity And An Acceptable Safety Profile In Preclinical Studies

Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.48) by 16.67 percent. This is a 16.67 percent decrease over losses of $(0.48) per share from the same period last year. The company reported quarterly sales of $1.27 million which beat the analyst consensus estimate of $891.50 thousand by 43.02 percent. This is a 11.03 percent decrease over sales of $1.43 million the same period last year.

Earnings Beats

Bolt Biotherapeutics Q2 EPS $(0.56) Misses $(0.48) Estimate, Sales $1.27M Beat $891.50K Estimate

Shares of Bolt Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) fell sharply during Wednesday's session after the company reported <a href="https://www.benzinga.com/quote/BOLT/earnings">first-quarter financial results</a>.
Bolt Biotherapeutics posted a GAAP loss of 28 cents per share on sales of $5.30 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
Also, Guggenheim analyst Michael Schmidt downgraded Bolt Biotherapeutics from Buy to Neutral, while Stifel analyst Stephen Willey downgraded the stock from Buy to Hold and lowered the price target from $6 to $1.5.
Bolt Biotherapeutics shares dipped 34.4% to $0.8652 on Wednesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>AERWINS Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWIN#NASDAQ">AWIN</a>) shares surged 201% to $8.16.</li>
<li>Sintx Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) jumped 169% to $0.1449 after jumping over 41% on Tuesday. SINTX Technologies recently posted downbeat quarterly results.</li>
<li>Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) jumped 87% to $0.5336 after jumping around 368% on Tuesday.</li>
<li>Edible Garden AG Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDBL#NASDAQ">EDBL</a>) climbed 53.2% to $6.54 following first-quarter results.</li>
<li>iPower Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPW#NASDAQ">IPW</a>) gained 53% to $1.36 after the company reported better-than-expected third-quarter financial results.</li>
<li>Selina Hospitality PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNA#NASDAQ">SLNA</a>) jumped 51% to $0.0850.</li>
<li>Greenwave Technology Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) shares gained 41% to $0.0627 after surging 7% on Tuesday.</li>
<li>Complete Solaria, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSLR#NASDAQ">CSLR</a>) gained 30.6% to $0.90. Complete Solaria signed a term sheet to eliminate Carlyle debt.</li>
<li>OptimizeRx Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) jumped 24% to $13.03 following upbeat quarterly results.</li>
<li>Blue Star Foods Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSFC#NASDAQ">BSFC</a>) rose 23% to $0.0686.</li>
<li>monday.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) jumped 21.5% to $220.93 after the company reported better-than-expected first-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>Telos Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLS#NASDAQ">TLS</a>) gained 21.4% to $3.85.</li>
<li>BioCryst Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) rose 20% to $6.44.</li>
<li>Arcutis Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) rose 16.5% to $9.47 after the company reported better-than-expected first-quarter financial results.</li>
<li>Dolphin Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLPN#NASDAQ">DLPN</a>) rose 15.4% to $1.2999 after the company reported a year-over-year increase in first-quarter financial results.</li>
<li>Codere Online Luxembourg, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDRO#NASDAQ">CDRO</a>) jumped 14.3% to $7.98 following first-quarter results.</li>
<li>Nutriband Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) gained 13.5% to $4.34.</li>
<li>Riskified Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSKD#NYSE">RSKD</a>) jumped 12.8% to $6.05 following upbeat results.</li>
<li>Cabaletta Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) gained 12.8% to $12.66 following first-quarter results.</li>
<li>Jeffs&#8217; Brands Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>) jumped 12% to $0.2530.</li>
<li>B&amp;G Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGS#NYSE">BGS</a>) rose 11.5% to $9.53.</li>
<li>Crown ElectroKinetics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRKN#NASDAQ">CRKN</a>) shares rose 11.2% to $0.0529.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) gained 8.1% to $0.0637 after adding around 12% on Tuesday.</li>
<li>Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) rose 6% to $142.18 after Morgan Stanley maintained an Overweight rating on the stock and raised its price target from $128 to $152.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares fell 63.9% to $0.8199 after the company reported pricing of $2.25m public offering.</li>
<li>Yield10 Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTEN#NASDAQ">YTEN</a>) fell 49.4% to $2.66 after the company reported delisting from the Nasdaq.</li>
<li>Aethlon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) fell 45.8% to $0.4604 after the company announced pricing of $4.7 million public offering.</li>
<li>Pixelworks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXLW#NASDAQ">PXLW</a>) dipped 40.2% to $1.1186 after the company issued soft second-quarter guidance.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) shares fell 31.9% to $33.22 following a 60% surge on Tuesday.</li>
<li>Koss Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOSS#NASDAQ">KOSS</a>) dipped 31% to $4.24.</li>
<li>VirTra, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTSI#NASDAQ">VTSI</a>) shares fell 30% to $11.49 after the company reported worse-than-expected first-quarter financial results.</li>
<li>MicroCloud Hologram Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NASDAQ">HOLO</a>) dipped 30.3% to $2.25.</li>
<li>SunPower Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWR#NASDAQ">SPWR</a>) shares fell 29.6% to $3.0896. Wolfe Research analyst Steve Fleishman downgraded SunPower from Peer Perform to Underperform.</li>
<li>Intrusion Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) shares declined 28.7% to $1.84 after the company reported downbeat first-quarter sales.</li>
<li>DLocal Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLO#NASDAQ">DLO</a>) fell 27.5% to $9.84 after the company reported weaker-than-expected first-quarter earnings and said there is a greater likelihood of coming in towards the lower end of its guidance range.</li>
<li>AMC Entertainment Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) fell 26.3% to $5.04 after jumping 32% on Tuesday.</li>
<li>Maxeon Solar Technologies, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAXN#NASDAQ">MAXN</a>) declined 25% to $2.7550.</li>
<li>The Oncology Institute, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) fell 24.4% to $0.6798 following weak quarterly results.</li>
<li>Cheetah Net Supply Chain Service Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NASDAQ">CTNT</a>) shares fell 23.2% to $4.92 after jumping 442% on Tuesday. The company priced a follow-on offering for gross proceeds of $8.19 million.</li>
<li>Nortech Systems Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSYS#NASDAQ">NSYS</a>) fell 21.1% to $11.97. Nortech Systems is expected to hold a conference call on Thursday, May 16, to discuss the company&#8217;s first quarter financial results.</li>
<li>Virgin Galactic Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NASDAQ">SPCE</a>) fell 16.5% to $1.06.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) declined 12.5% to $11.80.</li>
<li>Pulse Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) declined 12.1% to $6.74. Pulse Biosciences named Burke T. Barrett as President and Chief Executive Officer.</li>
<li>iRobot Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) fell 11.8% to $11.24.</li>
<li>BlackBerry Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) fell 10.2% to $3.11.</li>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) fell 9.9% to $4.8000.</li>
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) dipped 9.5% to $5.24. New reports indicate the company on Wednesday launched its first vehicle under its new Onvo brand.</li>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) fell 8.7% to $10.22.</li>
<li>Petróleo Brasileiro S.A. &#8211; Petrobras (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBR#NYSE">PBR</a>) shares fell 8.3% to $15.30. Brazil's President Luiz Inacio Lula da Silva fired Jean Paul Prates, the CEO of Petrobras, following a dispute over dividend.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/05/38844468/jim-cramer-this-industrial-company-is-absolutely-terrific-recommends-buying-modine-manufacturing">Jim Cramer: This Industrial Company Is &#8216;Absolutely Terrific&#8217;, Recommends Buying Modine Manufacturing</a>

Intraday Update

Markets

Movers

AEMD

ARQT

AWIN

BCRX

BSFC

CABA

CDRO

CRKN

CSLR

CTNT

DELL

DLPN

EDBL

FFIE

GWAV

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

INTZ

IRBT

JFBR

KOSS

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MNDY

NOVA

NSYS

NTRB

NVAX

OPRX

PEGY

PLSE

PXLW

RIVN

RSKD

SINT

SLNA

SPCE

SPWR

VRPX

VTSI

YTEN

Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Leerink Partners analyst Daina Graybosch downgrades Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) from Outperform to Market Perform and lowers the price target from $3 to $1.

Downgrades

Price Target

Leerink Partners Downgrades Bolt Biotherapeutics to Market Perform, Lowers Price Target to $1

<h3>Gainers</h3>
<ul>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock moved upwards by 136.2% to $0.13 during Wednesday's regular session. The company's market cap stands at $15.9 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>T2 Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) shares moved upwards by 45.55% to $6.06. The company's market cap stands at $81.9 million. </li>
<li>Nutriband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) shares rose 25.9% to $4.67. The company's market cap stands at $51.2 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares increased by 25.64% to $2.89. The company's market cap stands at $2.5 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) shares moved upwards by 22.8% to $12.87. The market value of their outstanding shares is at $234.0 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock increased by 20.57% to $1.0. The market value of their outstanding shares is at $50.7 million. As per the news, the Q1 earnings report came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) stock decreased by 67.0% to $0.76 during Wednesday's regular session. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock fell 50.35% to $0.42. The company's market cap stands at $1.1 million. </li>
<li>Yield10 Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTEN#NASDAQ">YTEN</a>) stock decreased by 37.84% to $3.27. The company's market cap stands at $2.1 million. </li>
<li>Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) shares declined by 33.12% to $0.88. The company's market cap stands at $33.6 million. The company's, Q1 earnings came out yesterday. </li>
<li>Oncology Institute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) shares fell 18.91% to $0.73. The market value of their outstanding shares is at $54.2 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) shares declined by 18.27% to $1.61. The market value of their outstanding shares is at $3.6 million. The company's, Q1 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BBLG

EYEN

TCON

TTOO

12 Health Care Stocks Moving In Wednesday's Intraday Session

Jones Trading analyst Soumit Roy downgrades Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) from Buy to Hold.

Jones Trading Downgrades Bolt Biotherapeutics to Hold

HC Wainwright &amp; Co. analyst Edward White downgrades Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) from Buy to Neutral.

HC Wainwright & Co. Downgrades Bolt Biotherapeutics to Neutral

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Deutsche Bank analyst Bryan Keane downgraded the rating on Accenture plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) from Buy to Hold, while slashing the price target from $409 to $295. Accenture shares declined 0.2% to close at $306.95 on Tuesday. <a href="https://www.benzinga.com/quote/ACN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel analyst Stephen Willey downgraded Bolt Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) from Buy to Hold and lowered the price target from $6 to $1.5. Bolt Biotherapeutics shares slipped 0.8% to settle at $1.32 on Tuesday. <a href="https://www.benzinga.com/quote/BOLT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wolfe Research analyst Steve Fleishman downgraded the rating for SunPower Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWR#NASDAQ">SPWR</a>) from Peer Perform to Underperform. SunPower shares jumped 59.6% to settle at $4.39 on Tuesday. <a href="https://www.benzinga.com/quote/SPWR/analyst-ratings">See how other analysts view this stock. See how other analysts view this stock.</a></li>
<li>B. Riley Securities analyst Lucas Pipes downgraded A-Mark Precious Metals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRK#NASDAQ">AMRK</a>) from Buy to Neutral, but maintained the price target of $33. A-Mark Precious Metals shares gained 7.2% to close at $39.80 on Tuesday. <a href="https://www.benzinga.com/quote/AMRK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank analyst Chris Woronka downgraded the rating for Six Flags Entertainment Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIX#NYSE">SIX</a>) from Buy to Hold, while lowering the price target from $29 to $27. Six Flags Entertainment shares slipped 0.6% to settle at $26.72 on Tuesday. <a href="https://www.benzinga.com/quote/SIX/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/05/38839679/top-3-consumer-stocks-that-could-blast-off-this-month">Top 3 Consumer Stocks That Could Blast Off This Month</a>

Trading Ideas

AMRK

This Accenture Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Today

Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) rose sharply in today's pre-market trading after the company reported better-than-expected <a href="https://www.benzinga.com/general/biotech/24/05/38830997/arcutis-biotherapeutics-stock-climbs-after-blockbuster-q1-results">first-quarter financial results</a>.
Arcutis Biotherapeutics reported quarterly earnings of 32 cents per share which beat the analyst consensus estimate of losses of 73 cents. Quarterly sales clocked in at $49.57 million, beating the analyst consensus estimate of $14.68 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Arcutis Biotherapeutics shares jumped 29% to $10.49 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) gained 113.8% to $0.6098 in pre-market trading after jumping around 368% on Tuesday.</li>
<li>Sintx Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) gained 94.8% to $0.1072 in pre-market trading after jumping over 41% on Tuesday. SINTX Technologies recently posted downbeat quarterly results.</li>
<li>Greenwave Technology Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) shares gained 41.8% to $0.0631 in pre-market trading after surging 7% on Tuesday.</li>
<li>Dolphin Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLPN#NASDAQ">DLPN</a>) rose 28.8% to $1.45 in today's pre-market trading after the company reported a year-over-year increase in first-quarter financial results.</li>
<li>Crown ElectroKinetics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRKN#NASDAQ">CRKN</a>) shares rose 17.7% to $0.0560 in pre-market trading.</li>
<li>Bitfarms Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BITF#NASDAQ">BITF</a>) shares rose 16.2% to $1.87 in pre-market trading.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) gained 14.6% to $0.0675 in pre-market trading after adding around 12% on Tuesday.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) shares climbed 12.1% to $54.64 in pre-market trading following a 60% surge on Tuesday.</li>
<li>AMC Entertainment Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) gained 10.6% to $7.58 in pre-market trading after jumping 32% on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares declined 40.1% to $1.36 in pre-market trading after dipping 20% on Tuesday. Virpax Pharmaceuticals recently reported a year-over-year decrease in first-quarter EPS results.</li>
<li>Bolt Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) shares fell 31.8% to $0.9008 in pre-market trading after the company reported first-quarter financial results.</li>
<li>DLocal Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLO#NASDAQ">DLO</a>) fell 26.7% to $9.95 in pre-market trading after the company reported weaker-than-expected first-quarter earnings and said there is a greater likelihood of coming in towards the lower end of its guidance range.</li>
<li>Intrusion Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) shares declined 25.2% to $1.93 in pre-market trading after the company reported downbeat first-quarter sales.</li>
<li>Cheetah Net Supply Chain Service Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NASDAQ">CTNT</a>) shares fell 25.2% to $4.79 in pre-market trading after jumping 442% on Tuesday. The company priced a follow-on offering for gross proceeds of $8.19 million.</li>
<li>Aethlon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares dipped 21.8% to $0.6650 in pre-market trading after falling 14% on Tuesday.</li>
<li>VirTra, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTSI#NASDAQ">VTSI</a>) shares fell 20.5% to $13.05 in pre-market trading after the company reported worse-than-expected first-quarter financial results.</li>
<li>SunPower Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWR#NASDAQ">SPWR</a>) shares fell 10.6% to $3.93 in pre-market trading after jumping around 60% on Tuesday.</li>
<li>Allogene Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLO#NASDAQ">ALLO</a>) shares declined 8.8% to $2.70 in pre-market trading. Allogene Therapeutics filed for offering of up to 37.93 million shares of common stock.</li>
<li>Petróleo Brasileiro S.A. &#8211; Petrobras (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBR#NYSE">PBR</a>) shares fell 8.6% to $15.25 in pre-market trading. Brazil's President Luiz Inacio Lula da Silva fired Jean Paul Prates, the CEO of Petrobras, following a dispute over dividend.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/05/38835371/cisco-prestige-consumer-healthcare-and-3-stocks-to-watch-heading-into-wednesday">Cisco, Prestige Consumer Healthcare And 3 Stocks To Watch Heading Into Wednesday</a>

Pre-Market Outlook

ALLO

BITF

Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock moved upwards by 143.1% to $0.13 during Wednesday's pre-market session. The company's market cap stands at $16.4 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>Arcutis Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) stock increased by 18.92% to $9.67. The market value of their outstanding shares is at $1.1 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>MultiPlan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLN#NYSE">MPLN</a>) stock increased by 17.24% to $0.66. The market value of their outstanding shares is at $426.5 million. </li>
<li>CASI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASI#NASDAQ">CASI</a>) shares moved upwards by 15.45% to $3.66. The company's market cap stands at $49.0 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Dynatronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYNT#NASDAQ">DYNT</a>) shares increased by 15.11% to $0.47. The market value of their outstanding shares is at $2.2 million. As per the news, the Q3 earnings report came out 4 days ago. </li>
<li>Virios Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRI#NASDAQ">VIRI</a>) stock rose 14.4% to $0.44. The market value of their outstanding shares is at $8.4 million. The company's, Q1 earnings came out 4 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) stock decreased by 60.5% to $0.91 during Wednesday's pre-market session. The company's market cap stands at $1.0 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) stock decreased by 29.56% to $0.93. The market value of their outstanding shares is at $35.4 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) stock decreased by 19.29% to $1.59. The market value of their outstanding shares is at $3.6 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Vivos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) stock fell 18.48% to $2.03. The market value of their outstanding shares is at $6.0 million. The company's, Q1 earnings came out yesterday. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock decreased by 17.78% to $0.7. The market value of their outstanding shares is at $1.8 million. </li>
<li>Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) stock declined by 13.45% to $0.29. The market value of their outstanding shares is at $42.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CASI

DYNT

MPLN

RBOT

VIRI

VVOS

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

WIIM

Bolt Biotherapeutics shares are trading lower after the company reported Q1 financial results. Also, multiple firms downgraded their respective price targets on the stock.

Guggenheim analyst Michael Schmidt downgrades Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) from Buy to Neutral.

Guggenheim Downgrades Bolt Biotherapeutics to Neutral

Stifel analyst Stephen Willey downgrades Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) from Buy to Hold and lowers the price target from $6 to $1.5.

Stifel Downgrades Bolt Biotherapeutics to Hold, Lowers Price Target to $1.5

Bolt Biotherapeutics shares are trading lower. The company reported Q1 financial results.

Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.49) by 42.86 percent. The company reported quarterly sales of $5.30 million which beat the analyst consensus estimate of $2.06 million by 156.88 percent. This is a 190.25 percent increase over sales of $1.83 million the same period last year.

Bolt Biotherapeutics Q1 2024 GAAP EPS $(0.28) Beats $(0.49) Estimate, Sales $5.30M Beat $2.06M Estimate

<h3>Gainers</h3>
<ul>
<li>Arcutis Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) stock moved upwards by 16.4% to $9.46 during Tuesday's after-market session. The company's market cap stands at $1.0 billion. As per the press release, Q1 earnings came out today. </li>
<li>BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) stock rose 13.02% to $2.95. The market value of their outstanding shares is at $141.9 million. As per the news, the Q1 earnings report came out today. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) stock increased by 7.55% to $11.25. The company's market cap stands at $204.5 million. As per the news, the Q1 earnings report came out today. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock moved upwards by 6.74% to $0.93. The market value of their outstanding shares is at $12.4 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares rose 6.08% to $2.44. The market value of their outstanding shares is at $2.1 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) stock rose 5.81% to $0.06. The market value of their outstanding shares is at $7.1 million. As per the press release, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) stock fell 15.9% to $1.11 during Tuesday's after-market session. The market value of their outstanding shares is at $42.3 million. </li>
<li>Vivos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) stock declined by 12.86% to $2.17. The company's market cap stands at $6.4 million. The company's, Q1 earnings came out today. </li>
<li>Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) shares decreased by 12.0% to $2.71. The company's market cap stands at $44.0 million. As per the press release, Q1 earnings came out today. </li>
<li>Prestige Consumer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBH#NYSE">PBH</a>) stock fell 7.66% to $66.0. The market value of their outstanding shares is at $3.2 billion. As per the press release, Q4 earnings came out today. </li>
<li>Akili (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKLI#NASDAQ">AKLI</a>) shares decreased by 7.32% to $0.41. The market value of their outstanding shares is at $32.4 million. As per the news, the Q1 earnings report came out today. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares fell 5.77% to $1.47. The market value of their outstanding shares is at $50.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKLI

BCAB

IRIX

OCEA

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Aesthetic Medical Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIH#NASDAQ">AIH</a>) shares rose 14.0% to $0.52 during Wednesday's after-market session. The company's market cap stands at $24.9 million. </li>
<li>Kineta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KA#NASDAQ">KA</a>) shares rose 8.46% to $0.58. The company's market cap stands at $6.3 million. </li>
<li>Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) shares increased by 6.74% to $40.99. The market value of their outstanding shares is at $818.4 million. As per the news, the Q2 earnings report came out today. </li>
<li>Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) shares moved upwards by 6.66% to $1.44. The company's market cap stands at $54.9 million. </li>
<li>Eiger BioPharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EIGR#NASDAQ">EIGR</a>) shares increased by 6.66% to $1.76. The market value of their outstanding shares is at $2.6 million. </li>
<li>Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) shares rose 5.38% to $4.5. The company's market cap stands at $236.2 million. As per the news, the Q4 earnings report came out 4 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Connect Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTB#NASDAQ">CNTB</a>) shares fell 10.8% to $1.9 during Wednesday's after-market session. The company's market cap stands at $104.6 million. </li>
<li>Acorda Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOR#NASDAQ">ACOR</a>) stock fell 10.4% to $1.81. The market value of their outstanding shares is at $2.2 million. As per the news, the Q4 earnings report came out 2 days ago. </li>
<li>Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) shares decreased by 8.54% to $2.25. The market value of their outstanding shares is at $181.8 million. </li>
<li>Qilian Intl Hldg Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLI#NASDAQ">QLI</a>) shares declined by 8.51% to $0.64. The market value of their outstanding shares is at $22.8 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares fell 7.33% to $2.53. The company's market cap stands at $9.2 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) shares declined by 6.33% to $6.07. The company's market cap stands at $5.3 million. As per the press release, Q4 earnings came out 4 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACOR

CNTB

EIGR

HSDT

IPHA

12 Health Care Stocks Moving In Wednesday's After-Market Session

Bolt Biotherapeutics (BOLT) just unveiled an update. Bolt Biotherapeutics, Inc. announced board changes with the resignations of James Healy and Fr...

Bolt Biotherapeutics Announces Board Reshuffle and New Appointment

Bolt Biotherapeutics (BOLT) presented updated preclinical data for BDC-4182, a next-generation Boltbody ISAC clinical candidate targeting claudin 1...

Bolt Biotherapeutics presents updated preclinical data for BDC-4182

Reports Q3 revenue $1.14M, consensus $1.26M."During the third quarter, we continued to make progress with our two proprietary programs, BDC-3042 an...

Bolt Biotherapeutics reports Q3 EPS (40c), consensus (35c)

In a report released today, Edward White from H.C. Wainwright maintained a Hold rating on Bolt Biotherapeutics (BOLT – Research Report). The compan...

H.C. Wainwright Reaffirms Their Hold Rating on Bolt Biotherapeutics (BOLT)

In a report released today, Stephen Willey from Stifel Nicolaus maintained a Hold rating on Bolt Biotherapeutics (BOLT – Research Report), with a p...

Stifel Nicolaus Remains a Hold on Bolt Biotherapeutics (BOLT)

Bolt Biotherapeutics GAAP EPS of -$0.40, revenue of $1.14M

Bolt Biotherapeutics reports Q3 results

Bolt Biotherapeutics, Inc. ( ($BOLT) ) has released its Q3 earnings. Here is a breakdown of the information Bolt Biotherapeutics, Inc. presented to...

Bolt Biotherapeutics Reports Q3 2024 Financial Results

Bolt Biotherapeutics, Inc. (BOLT) has disclosed a new risk, in the Corporate Activity and Growth category. The restructuring initiative undertaken ...

Bolt Biotherapeutics' Restructuring Faces Potential Setbacks: A Closer Look

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Tenaya Therapeutics (TNYA – Research Report), Bolt Biotherapeutic...

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Bolt Biotherapeutics (BOLT) and Amarin (AMRN)

AMRN

TNYA

Press Releases

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

Legal

BOLT DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important September 3 Deadline in Securities Class Action – BOLT

BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Penny Stocks

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLT

Management

Bolt Biotherapeutics Announces Changes to its Board of Directors

Health Care

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Comments

Bolt Biotherapeutics

Notizie

Ultime notizie per Bolt Biotherapeutics (NASDAQ:BOLT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO